Cover Image
市場調查報告書

停經後骨質疏鬆症:開發中產品分析

Post Menopausal Osteoporosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213136
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
停經後骨質疏鬆症:開發中產品分析 Post Menopausal Osteoporosis - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 85 Pages
簡介

所謂停經後骨質疏鬆症,是骨質疏鬆症最常見的形態,很多停經後的女性罹患。症狀有背痛和身高降低,駝背姿勢等脊椎變形。風險係數有年齡、性別、家族病史、骨結構、體重等,治療方法有荷爾蒙補充療法(HRT),維他命D3衍生物的給藥等。

本報告涵括全球停經後骨質疏鬆症治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

停經後骨質疏鬆症概要

治療藥的開發

  • 開發中產品的概要

停經後骨質疏鬆症:企業開發中的治療藥

停經後骨質疏鬆症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

停經後骨質疏鬆症:企業開發中的產品

停經後骨質疏鬆症的治療藥的開發企業

  • Amgen Inc.
  • BiologicsMD, Inc.
  • Clonz Biotech Private Limited
  • Eli Lilly and Company
  • Enteris BioPharma, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Paras Biopharmaceuticals Finland Oy
  • Radius Health, Inc.

停經後骨質疏鬆症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

停經後骨質疏鬆症:最近的開發平台趨勢

停經後骨質疏鬆症:暫停中的計劃

停經後骨質疏鬆症:開發中止的產品

停經後骨質疏鬆症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8575IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2016, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 5, 1, 1 and 6 respectively for Post Menopausal Osteoporosis.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post Menopausal Osteoporosis Overview
  • Therapeutics Development
    • Pipeline Products for Post Menopausal Osteoporosis - Overview
  • Post Menopausal Osteoporosis - Therapeutics under Development by Companies
  • Post Menopausal Osteoporosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Post Menopausal Osteoporosis - Products under Development by Companies
  • Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • BiologicsMD, Inc.
    • Eli Lilly and Company
    • Enteris BioPharma, Inc.
    • Intas Pharmaceuticals Ltd.
    • Ipsen S.A.
    • Ligand Pharmaceuticals, Inc.
    • NIBEC
    • Oncobiologics, Inc.
    • Paras Biopharmaceuticals Finland Oy
  • Post Menopausal Osteoporosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abaloparatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blosozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-1111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • calcitonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Postmenopausal Osteoporosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lasofoxifene tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romosozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post Menopausal Osteoporosis - Dormant Projects
  • Post Menopausal Osteoporosis - Discontinued Products
  • Post Menopausal Osteoporosis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
      • Sep 19, 2016: Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research 2016 Annual Meeting
      • Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR
      • Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
      • Sep 14, 2016: Amgen to present romosozumab at Investor Call
      • Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting
      • Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
      • Jul 21, 2016: Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
      • Jul 20, 2016: Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016
      • Jun 08, 2016: UCB presents Phase 3 data from the STRUCTURE study of Romosozumab at the Annual European Congress of Rheumatology (EULAR 2016)
      • May 31, 2016: Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
      • May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
      • Apr 15, 2016: Radius Announces Three Oral Presentations for Abaloparatide-SC at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease
      • Apr 01, 2016: Radius Presents Analysis Results on Fracture Risk Reduction in Phase 3 ACTIVE Trial for Investigational Drug Abaloparatide-SC at the ENDO 2016 Annual Meeting
      • Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post Menopausal Osteoporosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by BiologicsMD, Inc., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma, Inc., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Ipsen S.A., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by NIBEC, H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2016
  • Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Post Menopausal Osteoporosis - Dormant Projects, H2 2016
  • Post Menopausal Osteoporosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Post Menopausal Osteoporosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top